Ligand id: 7979

Name: dinutuximab

Compound class Antibody
Approved drug? Yes (FDA (2015))
International Nonproprietary Names
INN number INN
9754 dinutuximab
APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
A patent search identifies US20140170155 [4] as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay.
Database Links
Specialist databases
IMGT/mAb-DB 464
Other databases
GtoPdb PubChem SID 249565662
Search PubMed clinical trials dinutuximab
Search PubMed titles dinutuximab
Search PubMed titles/abstracts dinutuximab
Wikipedia Dinutuximab